Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Coya Therapeutics, Inc. - Common Stock
(NQ:
COYA
)
6.140
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Coya Therapeutics, Inc. - Common Stock
< Previous
1
2
Next >
COYA Stock Earnings: Coya Therapeutics Misses EPS, Misses Revenue for Q2 2024
August 12, 2024
COYA stock results show that Coya Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
7 Biotech Stocks to Put on Your Breakthrough Radar
May 27, 2024
Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance.
Via
InvestorPlace
EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases
May 27, 2024
Coya Therapeutics is working On neurodegenerative disease treatment with its combination therapies targeting regulatory T cells. CEO Howard Berman discusses the potential of COYA 302 for ALS, FTD,...
Via
Benzinga
COYA Stock Earnings: Coya Therapeutics Misses EPS for Q1 2024
May 09, 2024
COYA stock results show that Coya Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
COYA Stock Earnings: Coya Therapeutics Reported Results for Q4 2023
March 19, 2024
Coya Therapeutics just reported results for the fourth quarter of 2023.
Via
InvestorPlace
Coya Therapeutics
February 29, 2024
100% technical buy signals. 15 new highs and up 43.21% in the last month. 74.87+ Weighted Alpha
Via
Talk Markets
Analyst Expectations for Coya Therapeutics's Future
July 17, 2023
Via
Benzinga
The Latest Analyst Ratings for Coya Therapeutics
June 08, 2023
Via
Benzinga
Coya Therapeutics: Another Sucess
May 16, 2023
The Coya story is just beginning and as the company expands with larger trials, the success in those trials will only increase the valuation of the company.
Via
Talk Markets
Coya Therapeutics Secures Key Financing In Its Fight Against Myriad Diseases
February 05, 2024
Dr. Howard Burman, Ph.D, CEO and Dr. Arun Swaminathan, CBO, of Coya Therapeutics Inc (NASDAQ: COYA), were guests on Benzinga’s All Access.
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
December 01, 2023
Via
Benzinga
How The Same Treatments May Work For Multiple Neurodegenerative Diseases
September 21, 2023
Extensive research on NDDs has uncovered a different treatment pathway that's enabling some biotechnology firms to target more than one NDD with the same drug candidate.
Via
Talk Markets
12 Health Care Stocks Moving In Thursday's Intraday Session
September 07, 2023
Via
Benzinga
Coya Therapeutics' Alzheimer's Candidate Shows Lower Biomarker Levels Associated With Neuroinflammation
July 17, 2023
Coya Therapeutics Inc (NASDAQ: COYA) reported results from an open-label proof-of-concept clinical study for low-dose interleukin 2 (ld IL-2) in patients
Via
Benzinga
Why Coya Therapeutics Shares Are Shooting Higher Today
May 16, 2023
Coya Therapeutics Inc (NASDAQ: COYA) reported results from an open-label proof-of-concept clinical study for COYA 301 in
Via
Benzinga
The Immunotherapy Market Is Expected To Surpass $351.56 Billion By 2030 – Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) Is Contributing to This Growth
July 12, 2023
Immunotherapy, in general, is an exciting and growing sector in the pharmaceutical industry. It involves manipulating the human body's immune system to treat various diseases. While historically this...
Via
Benzinga
Marsh & McLennan To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday
June 08, 2023
Raymond James cut the price target for Brinker International, Inc. (NYSE: EAT) from $46 to $42.5. Raymond James analyst Brian Vaccaro maintained an Outperform rating. Brinker shares fell 6.3% to close...
Via
Benzinga
Blood Biomarker, Brain Imaging Data Shows Coya Therapeutics' Alzheimer's Candidate Lowers Neuroinflammation
June 07, 2023
Coya Therapeutics Inc (NASDAQ: COYA) reported additional biomarker and brain imaging results from an open-label proof-of-concept study for COYA 301 for
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
June 07, 2023
Via
Benzinga
Why Bluejay Diagnostics Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket
June 06, 2023
Gainers Visionary Education Technology Holdings Group Inc. (NASDAQ: VEDU) shares rose 85.8% to $0.7985 in pre-market trading.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
June 06, 2023
It's time for another dive into the latest pre-market stock movers as we check out all of the news moving shares on Tuesday morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
June 01, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
May 18, 2023
Via
Benzinga
Tesla, Manchester United, Ohmyhome, Target, Coya: Why These 5 Stocks Are Drawing Investor Attention Today
May 16, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
May 16, 2023
Via
Benzinga
Positive Financials Along With Promising Clinical Results – Coya Therapeutics
May 08, 2023
Howard Berman, Ph.D., CEO & Chairman of the Board of Coya Therapeutics, Inc. (NASDAQ: COYA), was recently a guest on Benzinga’s All Access.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2023
May 03, 2023
Via
Benzinga
Coya Therapeutics: An Attractive Valuation And First Set Of Data
April 19, 2023
Coya recent data in ALS seems under appreciated by the market and upcoming data in Alzheimer's offers the opportunity to confirm the early signals of efficacy in neurological conditions.
Via
Talk Markets
Alzheimer's Disease Largely Remains A Mystery, With A Lack Of Highly Effective Treatments — Could Regulatory T-Cells (Tregs) Be The Answer?
April 13, 2023
In many ways, Alzheimer's disease (AD) remains a mystery. Most common in those over 65, AD is the most common form of dementia, but its exact causes remain unclear, and treatments are unable to halt or...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
April 06, 2023
Via
Benzinga
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.